COPD

A component found in red wine and grapes may help manage inflammation caused by a bacterial pathogen associated with upper respiratory tract inflammatory diseases.

The rise in indoor temperatures worsened respiratory symptom scores and increased the use of recuse inhalers, a new study found.

COPD is the fourth leading cause of death in the United States, contributing to more than 120,000 deaths each year.

Focus on the early stages of chronic obstructive pulmonary disease could prevent long-term lung function loss.

The FDA has approved bevespi aerosphere inhalation aerosol for the long-term maintenance treatment of airflow obstruction in patients with COPD.

Risk of developing mental health issues were found to be lower in chronic obstructive pulmonary disease patients who are more active.

Patient persistence with AirFluSal Forspiro was twice the rate of Seretide Diskus.

COPD-related costs reduced from therapies that treat moderate-to-severe COPD.

Long-term culturing of stem cells may improve the treatment of respiratory conditions.

Chronic obstructive pulmonary disease patients who use opioids face a higher risk of respiratory-related death.

3M Drug Delivery Systems will be working to introduce its Intelligent Inhaler to the market by developing a partnership with pharmaceutical companies.

Medication targets the protein IL-33 that plays a role in asthma.

Caregivers need to carefully monitor comorbidities that accompany a COPD diagnosis.

Analysis of neutrophil behavior enhances understanding of chronic obstructive pulmonary disease.

There was a 210% increase in NTM occurrence in patients with COPD taking ICS.

Persistent VPC asthma was seen in 48% of patients in the TENOR II study.

Patients with COPD have less access to care, higher treatment costs, and lower standards of care.

The underlying mechanisms of the immune system may lead to new treatments for COPD and lupus.

Bacteria frequently found deep inside the lungs of chronic obstructive pulmonary disease patients.

Big data from social media may help anticipate emergency department visits for chronic conditions.

Bevespi Aerosphere is a twice-daily, fixed-dose dual bronchodilator combining a long-acting muscarcinic antagonist and a long-acting beta-2 agonist.

Bevespi Aerosphere is a twice-daily, fixed-dose dual bronchodilator.

The FDA has approved AstraZeneca's glycopyrrolate and formoterol fumarate (Bevespi Aerosphere) inhalation aerosol for long-term maintenance treatment for patients with chronic obstructive pulmonary disease.

Lack of social support among the leading risk factors for anxiety among COPD patients.

United States Preventive Services Task Force states screening for chronic obstructive pulmonary disease not be performed without symptoms of the disease.